Please provide your email address to receive an email when new articles are posted on . Blood dendritic cell antigen 2 and neonatal fragment crystallizable receptor are two novel strategies in lupus ...
Please provide your email address to receive an email when new articles are posted on . Patients with Sjögren’s disease treated with nipocalimab, a novel neonatal Fc receptor blocker, demonstrate ...
Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of FcRn-Targeted Therapies" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about FcRn-Targeted ...
Nipocalimab - the first neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus - is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated ...
Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic ...
In the ever changing biotherapeutics landscape, antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) success hinges on more than simply antigen recognition. While the Fab region controls ...
Autoimmune drug development increasingly recognizes that the Fc-FcR axis is more than an effector mechanism; it is a controllable immunological node that bridges humoral and cellular responses. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results